| abstract |
Recombinant, in particular humanised, e.g. humanisednchimeric and CDR-grafted humanised, antibody moleculesnhaving specificity for human TNFα, are provided for use inndiagnosis and therapy. In particular the antibody moleculesnhave antigen binding sites derived from murine monoclonalnantibodies CB0006, CB010, hTNF3 or 101.4. Preferred CDR-graftednhumanised anti-hTNFα antibodies comprise variablenregion domains comprising human acceptor framework and donornantigen binding regions and wherein the frameworks comprisendonor residues at specific positions. The antibodynmolecules may be used for therapeutic treatment of humannpatients suffering from or at risk of disorders associatednwith undesirably high levels of TNF, in particular forntreatment of immunoregulatory and inflammatory disorders ornof septic, endotoxic or cardiovascular shock. |